Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Gains from Investment Securities: 2017-2019

Historic Gains from Investment Securities for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2019 value amounting to -$317,000.

  • Astria Therapeutics' Gains from Investment Securities was N/A to -$317,000 in Q4 2019 from the same period last year, while for Dec 2019 it was -$1.6 million, marking a year-over-year change of. This contributed to the annual value of $5.8 million for FY2024, which is 12606.52% up from last year.
  • Astria Therapeutics' Gains from Investment Securities amounted to -$317,000 in Q4 2019, which was up 18.30% from -$388,000 recorded in Q3 2019.
  • Over the past 5 years, Astria Therapeutics' Gains from Investment Securities peaked at $3.8 million during Q1 2018, and registered a low of -$473,000 during Q2 2019.
  • Its 3-year average for Gains from Investment Securities is $278,736, with a median of $3,000 in 2017.
  • In the last 5 years, Astria Therapeutics' Gains from Investment Securities spiked by 13,883.80% in 2018 and then slumped by 419.59% in 2019.
  • Astria Therapeutics' Gains from Investment Securities (Quarterly) stood at $3,000 in 2017, then skyrocketed by 4,833.33% to $149,000 in 2018, then crashed by 360.40% to -$317,000 in 2019.
  • Its Gains from Investment Securities stands at -$317,000 for Q4 2019, versus -$388,000 for Q3 2019 and -$473,000 for Q2 2019.